Preotact is intact recombinant parathyroid hormone (1-84), which is given daily as 100µg subcutaneous injection in abdomen. Preotact is distinct from Forsteo (teriparatide), by containing the N-terminal amino acid sequence (1-34) of parathyroid hormone. There are no particular clinical differences between the two products in terms of efficiency or adverse effect in the treatment of osteoporosis in postmenopausal women with high risk of fractures. However, there is evidence of non-vertebral fracture prophylaxes with Forsteo, but not with Preotact. Both treatments are very expensive, Preotact being the less costly.
There is no general reimbursement for Preotact, but it is possible to apply for single reimbursement. The criteria of reimbursement for Preotact and Forsteo are similar.
Preotact was marketed in Denmark on 7 June 2006.
Institute for Rational Pharmacotherapy, 2 July 2006